Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

Radient Is Being Reorganized Through A Planned Reverse Merger

Radient Pharmaceuticals is being Reversed Merged with a private company that has been an ongoing plan since Onko-Sure was FDA approved in 2009. At the time of the FDA approval, Onko-Sure a/k/a DR-70 had two patents with only 4 and 5 years left to be protected under the Patent laws in the USA..In 2009, Mac formed a wholly owned subsidiary, it is named AMDL Diagnostics Inc. and is currently in Good Standing and incorporated in Delaware. It is controlled by Mac as president and Akio as the Secretary. The reason this corporation was formed, was to place Onko-Sure/Dr-70 assets and major distributor agreements into its umbrella for the upcoming merger plan, so they would be protected when Mac decided to voluntarily revoke the Stock with the SEC and make Radient a voided corporation in the state of Delaware. When Radient was delisted, they were placed on the Pink Sheets where the SEC rules were not as strict as the AMEX etc. Radient did not file annual reports for the years 2012, 2013, and 2014 before Mac voluntarily revoked the stock in April 2014..In order to revise the corporation, all annual reports have to be updated, as well as those to reinstate the corporation in Delaware..It only takes around 30 days for this procedure.As it appears now, Radient is considered a shell Corporation with no assets, and no business..It has around 300 to 500 thousand dollars of accounts payable that most are over four years old.Beyond the 4 year statute of limitations in California where Radient was incorporated as a domestic corporation..In Delaware it is considered a foreign Corporation. There is no debt with any lenders according to the SEC and the PR's that came out in 2011..All the lenders agreed to a debt for equity plan where their debt would be converted into Radient Stock..This conversion took place in 2011 and accelerated in May 2012 and continued until July 2, 2014 when the stock was "temporarily" revoked...There were 4.5 billion shares outstanding with the authorized at 5 billion at the end of trading. Our Hypothesis is the following..The lenders could convert as many shares as they pleased. But, they were limited to the amount they could hold..In the 3 years of the lender converting, the company would at strategic times, place shares into the float. The lenders would purchase these shares up to the amount or percentage they were authorized to hold according to the SC 13'G's they filed before the conversions in 2012..All documented in the SEC filings. When they reached their limitations, they would sell those shares in the open market..The persons most interested in those shares would be the Angel investors who wanted to take control of Radient shares without controlling the company in the present but in the future. We believe they are the same angel investors who invested in the private company that wants to merge into the Radient Shell. This would allow them to have full control of RXPC stock, distributorship agreements, sales of Onko-Sure overseas especially India, Korea,Taiwan etc. and the IP's,Dr-70, and the "Diamond In The Rough" that being CIT... When these investors purchase shares quietly over a 3 year period,it is called a "Creeping Takeover Group" also known as a "Back Door Listing".In Radient's situation it is planned and non-hostile takeover. In our Hypothesis we will present Facts and Opinions and you can weigh in what you and we believe is going on behind the scenes you understand...

Radient has two IP's..Dr-70 and CIT. On April 8, 2010 there was a PR that came out in relation to CIT. Here is that PR and why the pps increased 10 fold in 6 trading days..The result of this PR also was the start of two major investors, one we believe is connected to the private company who wants to takeover Radient..Here is the PR and our analysis..We believe the main reason for the takeover is the CIT. Dr-70 is also important as well as the Shell for the private company to go public.

http://www.dancewithshadows.com/pillscribe/jaiva-to-trial-radients-new-cancer-vaccine-combination-immunogene-therapy-technology-in-india/

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112869092

http://www.biomedreports.com/2010040735249/rxnews-recap-for-wednesday-04-07-10.html

Why has this been so quiet over the years..Because of a confidentiality clause within the agreement.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112870672

Here are the two investors that filed SC 13'G's and Form D immediately after the PR about Jaiva and CIT in India on April 8, 2010.The first one is John Fife and his firm
ISP Holdings.

Filed April 22, 2010

http://www.sec.gov/Archives/edgar/data/838879/000148932010000004/0001489320-10-000004-index.htm

http://www.sec.gov/Archives/edgar/data/838879/000148932010000004/main.txt

This is the most interesting Investor..If you notice in the filings they invested over 11 million dollars and it includes 36 investors. This is around the same amount of Angel Investors that had also invested 6 million dollars in the private company in September 2011 that wants to reverse merge with Radient. The attorney who set up this offering is also the attorney firm that agreed to take 300,000 dollars of services rendered in lieu of Radient stock that would be available to that firm on April 30, 2015, a waiting period on their part of 2 years. The attorney who arranged and signed the offering also is a Reverse Merger specialist. Here is the company that invested 11 million dollars..It is a well known hedge fund company called Capital Venture International, they are managed in the USA by Heights Capital


http://www.sec.gov/Archives/edgar/data/838879/000083887910000003/0000838879-10-000003-index.htm

http://www.sec.gov/Archives/edgar/data/838879/000083887910000003/xslFormDX01/primary_doc.xml

http://www.sec.gov/Archives/edgar/data/838879/000110465910024011/a10-9019_1sc13g.htm

Here is the attorney and the law firm that represents Radient and the attorney who arranged and signed the offering to Capital Venture/Heights Capital.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112642646

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112642839

This is the agreement about the 300,000 dollars in services rendered in lieu of Radient Stock that will become available on April 30, 2015..We believe the attorneys knew about the reverse merger plan.Why would they take stock from a failing company unless there was some future value in that stock.


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112733314

What is AMDL Diagnostics role in the planned reverse merger in the upcoming years. We know it was set up in 2009 to place the assets and distributor agreements so when Radient went dormant, the company could still operate independently as a wholly owned subsidiary of Radient.It is a five year plan. Here is the PR to explain what their long term plan was to be in August 2009 and why we believe it is operating as an ongoing Delaware Corporation to allow Radient to continue being treated as a Shell.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112642646

On July 13, 2010 there was a PR that a private company from Arizona named Provista Diagnostics was going to be acquired by Radient. Here is the PR and the LOI to reverse merge.

July 13, 2010

http://www.pharmpro.com/news/2010/07/radient-pharmaceuticals-acquire-provista-diagnostics-inc

The reason for the reverse merger is explained in the next two PR's. Provista and Radient had a successful screening cancer test when Dr-70 was combined with Provista's patented antibodies and Biomarkers..The combination was used for Provista's BT Test for Cancer and for Lung Cancer. The Lung Cancer Test combination was called "LC Sentinel".

October 14, 2010

http://www.pharmaceuticalonline.com/doc/radient-pharmaceuticals-and-provista-life-0001

November 12, 2010

http://www.bizjournals.com/phoenix/print-edition/2010/11/12/provista-developing-early-test.html

During the time of the announced LOI reverse merger between Radient and Provista Diagnostics, This next PR contains a very important aspect of the planned reverse merger. It allowed Provista Diagnostics a five year exclusive LSP arrangement to research and develop new products and services for the use of DR-70.The agreement ends in November 2015. The details are included in the PR. This was part of the plan to allow Provista to use DR-70 while Radient was dormant and during and after the patents expired. The use is under agreement with a confidentiality clause and a non- compete clause. Radient has full protection after the patent expired because of this agreement..This is why it was set up in the first place.

November 2, 2010

http://www.marketwired.com/press-release/Radient-Pharmaceuticals-Announces-Exclusive-5-Year-Laboratory-Services-Agreement-With-NYSE-Amex-RPC-1345331.htm

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111963874

What is Onko-Sure a/k/a Dr-70. Here is a PR that came out on April 8, 2010, the same day Jaiva and the Phase II and Phase III trials for CIT were announced to take place in India.



http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112735118

http://www.biomedreports.com/2010040835254/radients-fda-approved-diagnostic-test-detects-cancer-sooner.html

December 27, 2010 Interview with Mac

http://www.biomedreports.com/2010122761794/interview-with-the-ceo-of-radient-pharmaceuticals-amexrpc.html

Radient Pharmaceuticals: speculation intensifies over commercial potential of Onko-Sure cancer diagnostic test
13th Jan 2011,

http://www.proactiveinvestors.com/companies/news/11423/radient-pharmaceuticals-speculation-intensifies-over-commercial-potential-of-onko-sure-cancer-diagnostic-test-11423.html

Here is the hospital rumored to be where the Phase II and Phase III CIT trials took place.We speculate the funding is from SRL Diagnostics. Here are two links from DHRC in India.SRL Limited and Metropolis Healthcare are currently selling Onko-Sure as a General screening test..We believe Dr. B was at the conference for CIT and for Dr-70/Onko-Sure.

http://www.cancerhospitalindia.com/Guest-Lecture-07-Aug-2009-calender.html

http://www.dhrc.in/18-Mar-2011.html

CIT Patents

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112822784

October 20, 2011 CIT Law Suit Dismissed

http://finance.yahoo.com/news/Radient-Pharmaceuticals-iw-2149210956.html

The main reasons for the debt to equity conversions to Radient Stock. We believe that it was a plan to allow the lenders and the Provista Diagnostics Angel Investors to control Radient in the future by allowing the lenders to control around 34 per cent of RXPC stock and the Angel Invetsors around 56 per cent. The 90 percent is needed to control the Radient Shell once the Corporation is reinstated in Delaware and with the SEC.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112791737

January 27, 2011
Radient officials believe public spin-offs will bring full compliance and more value to shareholders

http://www.smallcapnetwork.com/Radient-officials-believe-public-spin-offs-will-bring-full-compliance-and-more-value-to-shareholders/s/article/view/p/mid/5/id/156/

Regarding latest 8k filing by Radient Pharmaceuticals- $RPC
May 11, 2011

http://seekingalpha.com/instablog/424698-m-e-garza/177461-regarding-latest-8k-filing-by-radient-pharmaceuticals-rpc

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112765409

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=112631347

What is LC Sentinel and who owns it. It is a collaboration between Provista Diagnostics and Radient. We will discuss in part two why we believe Global Cancer Diagnostics is and has developed the LC Sentinel Lung Cancer Test from the use of Dr-70 and Provista Diagnostics patented antibodies and Biomarkers. We will be presenting the rest of our hypothesis tomorrow morning with facts and opinions.

http://www.biocentury.com/products/lc_sentinel

http://www.biocentury.com/weekinreview/clinicalresults/2010-11-01/lc-sentinel-diagnostic-data-321886